Loading...
With millions of people now using glucagon-like peptide-1 (GLP-1) receptor agonists, new side effects have emerged, including changes in taste and smell. To explore these sensory effects further, researchers reviewed electronic health record data from 875,000 adults with type 2 diabetes, comparing those who received a GLP-1 agonist with similar patients who received other diabetes medications. Outcomes were assessed for up to 2 years, starting 3 months after treatment initiation.
The incidence of taste or smell disturbances was significantly higher in the GLP-1 group than in the control group (0.37% vs. 0.22%).
This difference reflects just one excess case of taste or smell disturbance for every ≈700 people treated with a GL…